Insider Purchases: Inside the Buy
Tag: CFO Insider Buying
Absci: When AI Meets Antibodies — and Insiders Can’t Resist Buying More!
AI is designing drugs, and Absci is leading the charge — with insider confidence, top-tier partners, and a cash runway through 2028. Still pre-revenue but packed with promise, this biotech might just be the next NVIDIA of antibodies.
Insiders Think Marvell Is a Wonder at Current Price; Should You Emulate the CEO, CFO, and Presidents and Buy MRVL?
Insiders, buybacks, and AI growth — oh my! Marvell Technology’s execs just bought millions in stock. With a $5B buyback, should you marvel too?
Novocure (NVCR): From Electric Fields to Fighting Cancer — and Maybe Lifting Portfolios?
Novocure is zapping cancer cells with Tumor Treating Fields — and maybe giving investors a shock of opportunity. With insiders and institutions piling in, can NVCR rebound 94% from its crash? ⚡📈
CEO, CFO, COO, and President, CooperVision, Are All Buying Shares of The Cooper Companies. Should You?
The CEO, CFO, COO, and President of CooperCompanies all just bought shares. Insiders, institutions, and even the company itself are betting on the stock. Value play or just another lens cleaner? 👓💸
Coty Class A (COTY): When Perfume Meets Portfolio
Coty’s stock is trading like discount lipstick, but insiders — including the CEO — are buying big. Is this a makeover moment or another smudge?
Eastman Chemical (EMN): Insider Chemistry at Work
Insiders from CEO to CFO are scooping up Eastman Chemical shares. With institutions owning 92% of the float and dividends flowing, is this a value play worth a reaction? 🧪📈
Amrize Will Rise, Insiders Undoubtedly Think
Amrize insiders are loading up on stock like it’s on sale at Home Depot. With infrastructure and housing tailwinds, it’s tempting — but watch out for valuation cracks.
MaxCyte (MXCT) — Insiders Load Up While Cash Burns
MaxCyte insiders are shopping biotech shares like it’s Black Friday 🛒💉. With revenue slipping, cash burning, but institutions holding, is MXCT a comeback spark ⚡ or a treadmill burn-out 🔥?
Financials Paint a Dire Story… But Tronox’s CEO and Insiders See Light in the TiO₂ Pigment
Tronox isn’t just about titanium dioxide anymore—it’s about insider confidence, global reach, and whether this chemical giant’s bright white future is worth your green 💵. From insider purchases to institutional moves, here’s why investors might want to watch TROX closely.
New CEO Buys In at Dave & Buster’s ($PLAY). Who Doesn’t Like a Little PLAY in Their Portfolio — or Life?
New CEO Tarun Lal takes the reins—and a big slice of $PLAY stock. With insiders buying, institutions overloaded, and sales trends improving, could this be the next comeback classic of the “entertainment” era?